
    
      This is a Phase IIa, open-label, multiple ascending dose confirmation, multicenter study to
      evaluate the safety and tolerability of intravenous SyB V-1901 0.2 mg/kg, 0.3 mg/kg, or 0.4
      mg/kg dosed BIW or 0.4 mg/kg dosed QW (Cohorts 1 to 4) in adult and pediatric subjects with
      AdV viremia. A total of 24 subjects aged 2 months and older will be enrolled: 6 subjects to
      each Cohort.
    
  